-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new version of the National Medical Insurance Catalogue will be officially launched nationwide from March 1st
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
The average price of the above five drugs dropped by 56.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
Subvert tradition
Leading pharmaceutical company in anti-diabetic drugs
According to data from the International Diabetes Federation, the number of diabetic patients in the world in 2019 was 463 million, which is expected to increase to 578 million by 2030, thus promoting the development of the anti-diabetic drug market
.
.
Statistics show that the sales of the world's leading 40 diabetes treatment drugs in 2020 will be 52.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
GLP-1 becomes the “leader” of non-insulin
Currently, sulfonylureas, thiazolidinediones, biguanides, α-glucosidase inhibitors and non-sulfonylurea secretion promoters have become common drugs, while glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors and a variety of insulin analogues have become the backbone of this field
.
.
In the global diabetes drug market in 2020, insulin accounted for 38.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
.
Statistics show that in 2020, the amount of global non-insulin drugs TOP20 will exceed 31 billion U.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
GLP-1 arena
Global sales exceed $13.
5 billion
5 billion
In recent years, the global peptide drug research and development pipeline has made great strides
.
.
Polypeptides are a class of compounds composed of 2-100 amino acids connected by peptide bonds
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
Small-molecule peptide drugs are a class of drugs that are developing rapidly in the field of diabetes
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
There are 7 GLP-1 receptor agonist hypoglycemic drugs on the market abroad, namely: short-acting exenatide, risenatide, liraglutide, long-acting exenatide microspheres, and abi Lutide, dulaglutide, semaglutide
.
.
According to the annual financial report of the multinational pharmaceutical industry, global GLP-1 receptor agonist sales in 2020 will exceed 13.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
Domestic original research and imitation flocks compete
On December 23, 2016, the National Medical Products Administration (NMPA) approved Shanghai Renhui Biopharmaceutical's original drug Beinaglutide 2.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
Prior to this, liraglutide, lixisenatide and exenatide have been included in the medical insurance catalogue
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
Continued rapid growth
According to Meinenet data, in 2020, the total amount of drugs used in public hospitals in key provinces and cities in China has exceeded 200 billion yuan, and the digestion, metabolism and anti-diabetic drug market accounted for 14.
34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
GLP-1 receptor agonists are a continuous and fast-growing category
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
Variety pattern
Liraglutide:
At present, the original research is monopolized, and the generic drugs are stepping up the layout
In July 2009, the liraglutide developed by Danish Novo Nordisk was approved by the European Union.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
Global sales of liraglutide reached a peak of 24.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
In March 2011, Novo Nordisk's liraglutide was approved to enter China under the trade name Novo Nordisk
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
At present, the domestic liraglutide market is exclusively dominated by Novo Nordisk's original research manufacturer Novo Nordisk
.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
Exenatide:
The market is declining, and new formulations are unstoppable
Exenatide is the first GLP-1 receptor agonist approved by the FDA.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
On October 30, 2009, Amylin announced that Exenatide has been approved by the FDA as a single drug for blood glucose control in type 2 diabetes
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
According to data from Meinenet, the amount of Exenatide (Byetta) used in public hospitals in key provinces and cities in China fell below 10 million yuan in 2020, down 42.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
Exenatide injection can improve the level of blood sugar control, protect β cells, delay the course of the disease, and reduce the risk of hypoglycemia and weight gain
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
The new version of the National Medical Insurance Catalogue will be officially launched nationwide from March 1st
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
The average price of the above five drugs dropped by 56.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
Subvert tradition
Leading pharmaceutical company in anti-diabetic drugs
According to data from the International Diabetes Federation, the number of diabetic patients in the world in 2019 was 463 million, which is expected to increase to 578 million by 2030, thus promoting the development of the anti-diabetic drug market
.
.
Statistics show that the sales of the world's leading 40 diabetes treatment drugs in 2020 will be 52.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
GLP-1 becomes the “leader” of non-insulin
Currently, sulfonylureas, thiazolidinediones, biguanides, α-glucosidase inhibitors and non-sulfonylurea secretion promoters have become common drugs, while glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors and a variety of insulin analogues have become the backbone of this field
.
.
In the global diabetes drug market in 2020, insulin accounted for 38.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
.
Statistics show that in 2020, the amount of global non-insulin drugs TOP20 will exceed 31 billion U.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
GLP-1 arena
Global sales exceed $13.
5 billion
5 billion
In recent years, the global peptide drug research and development pipeline has made great strides
.
.
Polypeptides are a class of compounds composed of 2-100 amino acids connected by peptide bonds
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
Small-molecule peptide drugs are a class of drugs that are developing rapidly in the field of diabetes
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
There are 7 GLP-1 receptor agonist hypoglycemic drugs on the market abroad, namely: short-acting exenatide, risenatide, liraglutide, long-acting exenatide microspheres, and abi Lutide, dulaglutide, semaglutide
.
.
According to the annual financial report of the multinational pharmaceutical industry, global GLP-1 receptor agonist sales in 2020 will exceed 13.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
Domestic original research and imitation flocks compete
On December 23, 2016, the National Medical Products Administration (NMPA) approved Shanghai Renhui Biopharmaceutical's original drug Beinaglutide 2.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
Prior to this, liraglutide, lixisenatide and exenatide have been included in the medical insurance catalogue
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
Continued rapid growth
According to Meinenet data, in 2020, the total amount of drugs used in public hospitals in key provinces and cities in China has exceeded 200 billion yuan, and the digestion, metabolism and anti-diabetic drug market accounted for 14.
34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
GLP-1 receptor agonists are a continuous and fast-growing category
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
Variety pattern
Liraglutide:
At present, the original research is monopolized, and the generic drugs are stepping up the layout
In July 2009, the liraglutide developed by Danish Novo Nordisk was approved by the European Union.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
Global sales of liraglutide reached a peak of 24.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
In March 2011, Novo Nordisk's liraglutide was approved to enter China under the trade name Novo Nordisk
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
At present, the domestic liraglutide market is exclusively dominated by Novo Nordisk's original research manufacturer Novo Nordisk
.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
Exenatide:
The market is declining, and new formulations are unstoppable
Exenatide is the first GLP-1 receptor agonist approved by the FDA.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
On October 30, 2009, Amylin announced that Exenatide has been approved by the FDA as a single drug for blood glucose control in type 2 diabetes
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
According to data from Meinenet, the amount of Exenatide (Byetta) used in public hospitals in key provinces and cities in China fell below 10 million yuan in 2020, down 42.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
Exenatide injection can improve the level of blood sugar control, protect β cells, delay the course of the disease, and reduce the risk of hypoglycemia and weight gain
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
The new version of the National Medical Insurance Catalogue will be officially launched nationwide from March 1st
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
.
The catalog contains 5 diabetes medications that have been successfully negotiated in the new round, namely: GLP-1 receptor agonist dulaglutide injection, polyethylene glycol loxenatide injection and benaglutide injection , SGLT-2 anti-diabetic drug Aeggliflozin tablets, new varieties of insulin family Degu aspart insulin injection
.
The average price of the above five drugs dropped by 56.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
85%
.
After the new anti-diabetic drugs quickly enter clinical use, they will further improve the level of diabetes management in China
.
Subvert tradition
Subvert tradition Leading pharmaceutical company in anti-diabetic drugs
Leading pharmaceutical company in anti-diabetic drugs According to data from the International Diabetes Federation, the number of diabetic patients in the world in 2019 was 463 million, which is expected to increase to 578 million by 2030, thus promoting the development of the anti-diabetic drug market
.
.
Statistics show that the sales of the world's leading 40 diabetes treatment drugs in 2020 will be 52.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
098 billion U.
S.
dollars
.
This lucrative field has attracted the interest of many pharmaceutical manufacturers, and new diabetes treatment drugs continue to flood the market, making Novo Nordisk, Eli Lilly, Merck, Boehringer Ingelheim, Sanofi, and AstraZeneca leading pharmaceutical companies
.
GLP-1 becomes the “leader” of non-insulin
GLP-1 becomes the “leader” of non-insulin Currently, sulfonylureas, thiazolidinediones, biguanides, α-glucosidase inhibitors and non-sulfonylurea secretion promoters have become common drugs, while glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors and a variety of insulin analogues have become the backbone of this field
.
.
In the global diabetes drug market in 2020, insulin accounted for 38.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
24%, and non-insulin drugs accounted for 61.
76%
.
Among them, GLP-1 receptor agonists accounted for 25.
98%, DPP-4 inhibitors accounted for 19.
35%, SGLT-2 inhibitors accounted for 14.
39%, and other hypoglycemic drugs accounted for 2.
04%
.
.
Statistics show that in 2020, the amount of global non-insulin drugs TOP20 will exceed 31 billion U.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
S.
dollars, an increase of 2.
29% year-on-year
.
GLP-1 receptor agonists have become the "leader" of non-insulin drugs in the world
.
GLP-1 arena
GLP-1 arena Global sales exceed $13.
5 billion
Global sales exceed $13. 5 billion
5 billion
In recent years, the global peptide drug research and development pipeline has made great strides
.
.
Polypeptides are a class of compounds composed of 2-100 amino acids connected by peptide bonds
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
.
Polypeptide drugs have the advantages of simple spatial structure, high stability, and low immunogenicity.
At the same time, they have the characteristics of strong specificity and good curative effect of protein drugs
.
According to data from the China Biochemical and Pharmaceutical Industry Association, global peptide drug sales in 2020 will exceed 30 billion U.
S.
dollars, showing explosive growth
.
Small-molecule peptide drugs are a class of drugs that are developing rapidly in the field of diabetes
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
.
GLP-1 is a peptide hormone secreted by human intestinal L cells, which can stimulate the proliferation and differentiation of β cells and promote insulin secretion
.
GLP-1 receptor agonists can not only play the role of lowering blood sugar, but also have better cardiovascular benefits, reducing food intake and delaying gastric emptying, which is conducive to weight control and weight loss
.
There are 7 GLP-1 receptor agonist hypoglycemic drugs on the market abroad, namely: short-acting exenatide, risenatide, liraglutide, long-acting exenatide microspheres, and abi Lutide, dulaglutide, semaglutide
.
.
According to the annual financial report of the multinational pharmaceutical industry, global GLP-1 receptor agonist sales in 2020 will exceed 13.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
5 billion U.
S.
dollars, an increase of 21.
71% over the previous year
.
Eli Lilly's dulaglutide and Novo Nordisk's semaglutide became the leading varieties
.
Domestic original research and imitation flocks compete
Domestic original research and imitation flocks compete On December 23, 2016, the National Medical Products Administration (NMPA) approved Shanghai Renhui Biopharmaceutical's original drug Beinaglutide 2.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
1ml: 4.
2mg injection, the trade name is Yishengtai
.
On May 5, 2019, NMPA approved the injection polyethylene glycol loxenatide of Jiangsu Hausen Pharmaceutical, the trade name is Fulaime
.
At present, a total of 7 GLP-1 models in China have been approved for listing
.
4 are short-acting products, namely: Exenatide from AstraZeneca, Liraglutide from Novo Nordisk, Benaglutide from Shanghai Renhui Biopharmaceuticals, Sanofi's Risnatide (Lismin)
.
The other 3 products are long-acting products, namely: AstraZeneca’s Exenatide Microspheres for Injection (Baidayan), Eli Lilly’s Dulaglutide (DuyiDa), and Jiangsu Hausen Pharmaceutical’s Polyethylene Loxenatide glycol
.
Prior to this, liraglutide, lixisenatide and exenatide have been included in the medical insurance catalogue
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
.
In 2020, the negotiation of dulaglutide, polyethylene glycol loxenatide and benaglutide will be successful
.
So far, all three long-acting GLP-1 models have been included in the medical insurance catalog
.
Continued rapid growth
Continued rapid growth According to Meinenet data, in 2020, the total amount of drugs used in public hospitals in key provinces and cities in China has exceeded 200 billion yuan, and the digestion, metabolism and anti-diabetic drug market accounted for 14.
34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
Procurement Procurement Procurement34%.
Under the influence of new policies such as the consistency evaluation of generic drugs, sunshine procurement and medical insurance negotiations, The anti-diabetic drugs in the public hospital market dropped by 6 percentage points
.
Non-insulin drugs TOP5 category DPP-4 inhibitors, biguanides, α-glucosidase inhibitors, sulfonylureas, GLP-1 receptor agonists accounted for more than 70%
.
GLP-1 receptor agonists are a continuous and fast-growing category
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
.
According to data from Minai.
com, the amount of GLP-1 receptor agonists used in public hospitals in key provinces and cities in China will exceed 300 million yuan in 2020, a year-on-year increase of 38.
42%
.
A cumulative increase of 196.
75% in the five years from 2016 to 2020
.
Variety pattern
Variety pattern Liraglutide:
Liraglutide: At present, the original research is monopolized, and the generic drugs are stepping up the layout
At present, the original research is monopolized, and the generic drugs are stepping up the layout In July 2009, the liraglutide developed by Danish Novo Nordisk was approved by the European Union.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
It was launched in Japan and the United States in 2010 under the trade name Victoza
.
At present, it has been approved for marketing in dozens of countries including Norway, Mexico, Iceland, Switzerland, Canada, and Russia.
The approved indications include type 2 diabetes and obesity
.
Global sales of liraglutide reached a peak of 24.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
333 billion Danish kroner in 2018.
After Novo Nordisk's new drug semaglutide was listed on the market, global sales of liraglutide will still reach 18.
747 billion Danish kroner in 2020
.
In March 2011, Novo Nordisk's liraglutide was approved to enter China under the trade name Novo Nordisk
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
.
According to data from Meinenet, in 2020, the amount of liraglutide used in public hospitals in key provinces and cities in China exceeded 200 million yuan, a year-on-year increase of 34.
93%, accounting for nearly 90% of the GLP-1 receptor agonist market in public hospitals
.
At present, the domestic liraglutide market is exclusively dominated by Novo Nordisk's original research manufacturer Novo Nordisk
.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
Enterprise Enterprise Enterprise Pharmaceutical Medicine Pharmaceutical Medicine Medicine Medicine Medicine.
As of the end of April 2021, many domestic companies have deployed liraglutide injection development
.
The drug registration applications of Shenzhen Jianxiang Biopharmaceuticals, Shenzhen Hanyu Pharmaceuticals, and Chengdu Shengnuo Biopharmaceuticals have been accepted by the State Food and Drug Administration
.
In addition, Tonghua Dongbao Pharmaceutical, Lianyungang Runzhong Pharmaceutical, Jiangsu Wanbang Biochemical Pharmaceutical , Chongqing Paijin Biotech, and Beijing Yizhuang International Protein Drug Technology have entered clinical development
.
Exenatide:
Exenatide: The market is declining, and new formulations are unstoppable
The market is declining, and new formulations are unstoppable Exenatide is the first GLP-1 receptor agonist approved by the FDA.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
It was approved in April 2005 under the trade name Byetta.
It was approved for clinical use as an oral hypoglycemic agent alone, which still cannot control blood glucose levels, but it has not been used yet.
Type 2 diabetes patients treated with insulin
.
On October 30, 2009, Amylin announced that Exenatide has been approved by the FDA as a single drug for blood glucose control in type 2 diabetes
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
.
On January 27, 2012, the US FDA approved Eli Lilly’s extended-release long-acting suspension injection of Exenatide under the trade name Bydureon
.
The drug is injected once a week, creating a precedent for long-acting hypoglycemic drugs
.
In 2020, AstraZeneca's Bydoreon and Byetta global sales were US$516 million, a year-on-year decrease of 21.
69%
.
According to data from Meinenet, the amount of Exenatide (Byetta) used in public hospitals in key provinces and cities in China fell below 10 million yuan in 2020, down 42.
90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
Hospital hospital hospital90% year-on-year, and only occupied 2.
7% of the GLP-1 market.
.
With product updates, it is predicted that Exenatide sustained-release and long-acting suspension injections will replace the Exenatide market
.
Exenatide injection can improve the level of blood sugar control, protect β cells, delay the course of the disease, and reduce the risk of hypoglycemia and weight gain
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
.
Qinghai Chenfei Pharmaceutical, Wuxi Hebang Biotechnology Co.
, Ltd.
has imitated Exenatide injections for registration in category 4 and is under review and approval
.
